Alector
Logotype for Alector Inc

Alector (ALEC) investor relations material

Alector Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Alector Inc
Q3 2026 earnings summary5 Nov, 2026

Executive summary

  • Q3 net income was $124.6 million, primarily reflecting recognition of $162.9 million in remaining GSK deferred revenue after performance obligations ended.

  • AL050 was licensed exclusively worldwide to Genentech for $100.0 million upfront, up to $1.17 billion in milestones and tiered royalties; the ABC platform was retained.

  • Pipeline focus shifted to ABC-enabled programs after GSK programs were discontinued; no active clinical trials were reported.

Financial highlights

  • Q3 collaboration revenue was $162.9 million vs. $3.3 million YoY, primarily from recognition of remaining GSK deferred revenue.

  • Q3 operating income was $123.8 million vs. an operating loss of $37.6 million YoY; net income was $124.6 million vs. a net loss of $34.7 million.

  • Q3 R&D was $30.0 million vs. $29.4 million; G&A was $9.0 million vs. $11.5 million YoY.

  • 9M revenue was $167.2 million vs. $14.8 million; net income was $78.7 million vs. a net loss of $105.7 million.

  • 9M R&D was $67.4 million vs. $90.6 million and G&A was $25.4 million vs. $40.6 million, mainly reflecting lower personnel costs after workforce reductions.

Outlook and guidance

  • Cash, cash equivalents and investments, plus the Genentech upfront payment and October offering proceeds net of the Spur payment, are expected to fund operations into 2H 2029; estimates depend on assumptions that may change.

  • AL137 first-in-human SC dosing in Australia is targeted by April 2027, with a U.S. IND submission targeted for Q2 2027; AL164 and AL062 first-in-human studies are targeted for Q2 2028.

  • R&D spending on latozinemab and nivisnebart is expected to decline as trials wind down, while investment continues in research and preclinical programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Alector earnings date

Logotype for Alector Inc
Q4 202625 Feb, 2027
Alector
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Alector earnings date

Logotype for Alector Inc
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company is developing AL001, an antibody that targets delta-like ligand 4-Notch to address abnormal signaling triggered by microglia in Alzheimer's disease prevention and slowing in patients with mild cognitive impairment and early-stage Alzheimer's disease; AL101, an anti-TREM2 antibody targeting microglia function that is in Phase IIa clinical trial for the treatment of frontotemporal dementia; AL003, an anti-LINGO monoclonal antibody targeting oligodendrocyte precursor cells for myelination; and AL002 and AL004 for preventing or slowing disease progression in Parkinson's disease. The company was founded in 2013 and is headquartered in South San Francisco, California.